In the article titled "The Controversial C5a Receptor C5aR2: Its Role in Health and Disease" \[[@B1]\], there was an error in Table 4, where Jun/fos-A8^△71--73^ should be corrected to A8^△71--73^. The corrected table is as follows:

###### 

C5aR2 agonists and antagonists.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ligand                                     Specificity                             Function                                                                      Refs
  ------------------------------------------ --------------------------------------- ----------------------------------------------------------------------------- --------------
  Jun/fos-A8\                                Human and murine C5aR1 and C5aR2        Antagonists---block binding of C5a and C5a\                                   \[51\]
  A8^△71--73^\                                                                       des Arg to C5aRs                                                              
  C5 mutant peptides                                                                                                                                               

  P32, P59---C terminal peptides of C5a      hC5aR2                                  Agonists---strongly stimulate the association of hC5aR2 with *β*-arrestin 2   \[21, 127\]

  LukS-PV---protein from *S. aureus*         Human and rabbit C5aR1\                 Antagonist of C5a-induced activation of neutrophils                           \[48, 128\]
                                             Human, macaque, and rabbit C5aR2                                                                                      

  HIgCB---protein complex from *S. aureus*   Human, macaque, rabbit, and cow C5aRs   Antagonist of C5a-induced activation of neutrophils                           \[128, 129\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
